Structural diversity and cytotoxic secondary metabolites from the endophytic fungus Chaetomium globosum

IF 1.7 4区生物学 Q4 CHEMISTRY, MEDICINAL

Phytochemistry Letters Pub Date : 2026-04-01 Epub Date: 2026-01-19 DOI:10.1016/j.phytol.2026.104119

Yizhou Bian , Sulu Qin , Shan Ran , Tao Zhu , Haiyan Fu , Wenjing Wang , Xiaolong Yang

{"title":"Structural diversity and cytotoxic secondary metabolites from the endophytic fungus Chaetomium globosum","authors":"Yizhou Bian , Sulu Qin , Shan Ran , Tao Zhu , Haiyan Fu , Wenjing Wang , Xiaolong Yang","doi":"10.1016/j.phytol.2026.104119","DOIUrl":null,"url":null,"abstract":"<div><div>Chemical investigation of the endophytic fungus Chaetomium globosum yielded two undescribed compounds: biscognin C (1), identified as a methyl-migrated analogue of biscognin B, and a rare ethyl-substituted dihydropyran derivative (2), together with seven known compounds (3−9). Their structures were unambiguously established through NMR, UV, HRESIMS, and ECD analysis. Compound 1 represents the first reported methyl-migrated biscognin analog, while compound 2 possesses an ethyl substitution distinct from dihydrodehydroacetic acid. Notably, the known compound 3 exhibited potent cytotoxicity against triple-negative breast cancer cells (MDA-MB-231) with an IC50 value of 1.64 μM. These findings expand the structural diversity of fungal secondary metabolites and highlight their potential as anticancer agents.</div></div>","PeriodicalId":20408,"journal":{"name":"Phytochemistry Letters","volume":"72 ","pages":"Article 104119"},"PeriodicalIF":1.7000,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Phytochemistry Letters","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1874390026000091","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/19 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Chemical investigation of the endophytic fungus Chaetomium globosum yielded two undescribed compounds: biscognin C (1), identified as a methyl-migrated analogue of biscognin B, and a rare ethyl-substituted dihydropyran derivative (2), together with seven known compounds (3−9). Their structures were unambiguously established through NMR, UV, HRESIMS, and ECD analysis. Compound 1 represents the first reported methyl-migrated biscognin analog, while compound 2 possesses an ethyl substitution distinct from dihydrodehydroacetic acid. Notably, the known compound 3 exhibited potent cytotoxicity against triple-negative breast cancer cells (MDA-MB-231) with an IC₅₀ value of 1.64 μM. These findings expand the structural diversity of fungal secondary metabolites and highlight their potential as anticancer agents.

查看原文本刊更多论文

内生真菌毛囊的结构多样性和细胞毒性次生代谢物

对内生真菌毛藻的化学研究得到了两种未描述的化合物：biscognin C(1)，鉴定为biscognin B的甲基迁移类似物，一种罕见的乙基取代双氢吡喃衍生物(2)，以及7种已知化合物（3−9）。通过NMR、UV、hresms和ECD分析明确了它们的结构。化合物1是首次报道的甲基迁移的铋素类似物，而化合物2具有不同于二氢脱氢乙酸的乙基取代。值得注意的是，已知化合物3对三阴性乳腺癌细胞（MDA-MB-231）表现出强大的细胞毒性，IC50值为1.64 μM。这些发现扩大了真菌次生代谢物的结构多样性，并突出了它们作为抗癌药物的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Phytochemistry Letters 生物-生化与分子生物学

CiteScore

3.00

自引率

11.80%

发文量

190

审稿时长

34 days

期刊介绍： Phytochemistry Letters invites rapid communications on all aspects of natural product research including: • Structural elucidation of natural products • Analytical evaluation of herbal medicines • Clinical efficacy, safety and pharmacovigilance of herbal medicines • Natural product biosynthesis • Natural product synthesis and chemical modification • Natural product metabolism • Chemical ecology • Biotechnology • Bioassay-guided isolation • Pharmacognosy • Pharmacology of natural products • Metabolomics • Ethnobotany and traditional usage • Genetics of natural products Manuscripts that detail the isolation of just one new compound are not substantial enough to be sent out of review and are out of scope. Furthermore, where pharmacology has been performed on one new compound to increase the amount of novel data, the pharmacology must be substantial and/or related to the medicinal use of the producing organism.